Background: Measurement of nitric oxide (NO) and nitrite/nitrates (NOx) levels in exhaled breath condensate (EBC) are non-invasive techniques, which can be used to monitor airway inflammatory diseases. Production of NO is often increased in inflammatory diseases of the airways, including exacerbations of chronic obstructive pulmonary disease (COPD). COPD-associated airway inflammation may be affected by multiple factors, including cigarette smoking and glucocorticosteroid (GCS) treatment. Objectives: To test the hypothesis that total NOx levels in EBC and exhaled NO levels would be affected by cigarette smoking or the presence of COPD. Methods: Exhaled NO levels and NOx levels in EBC were measured in 96 COPD patients and in 80 normal subjects. Results: Exhaled NO levels in COPD patients were significantly higher than those of normal subjects when comparing either the total groups (9.8 ± 0.7 vs. 5.5 ± 0.4 ppb, p < 0.0005) or 2 appropriate subgroups, ex-smokers (10.3 ± 1.0 vs. 5.4 ± 0.6 ppb, p < 0.0005) and smokers (9.2 ± 1.2 vs. 5.7 ± 0.5 ppb, p = 0.002). There was no significant difference in NOx levels in EBC, however, between COPD patients and healthy subjects when analysed either together or as subgroups. No significant difference was found in either exhaled NO levels or NOx levels in EBC between GCS-naïve subjects and those on GCS treatment in the ex-smoking or smoking COPD subgroups. Conclusions: COPD patients have higher exhaled NO levels than control subjects when either combined or analysed as non-smoking, ex-smoking and smoking subgroups. GCS treatment did not appear to affect these non-invasive markers of airway inflammation in COPD.

Keywords:
Chronic obstructive pulmonary disease, Exhaled breath condensate, Glucocorticosteroids, Nitric oxide, Smoking
1.
Chladkova J, Krcmova I, Chladek J, Cap P, Micuda S, Hanzalkova Y: Validation of nitrite and nitrate measurements in exhaled breath condensate. Respiration 2006;73:173–179.
2.
Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ: Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995;152:609–612.
3.
Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ: Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133–135.
4.
Yates DH, Kharitonov SA, Robbins RA, Thomas PS, Barnes PJ: Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. Am J Respir Crit Care Med 1995;152:892–896.
5.
Liu J, Thomas PS: Cigarette smoking increases nitrite/nitrate in exhaled breath condensate (abstract). Respirology 2004;9:A40.
6.
Kharitonov SA, Yates DH, Barnes PJ: Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996;153:454–457.
7.
Robbins RA, Barnes PJ, Springall DR, Warren JB, Kwon OJ, Buttery LD, Wilson AJ, Geller DA, Polak JM: Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun 1994;203:209–218.
8.
Raij L, DeMaster EG, Jaimes EA: Cigarette smoke-induced endothelium dysfunction: role of superoxide anion. J Hypertens 2001;19:891–897.
9.
Tsuchiya M, Asada A, Kasahara E, Sato EF, Shindo M, Inoue M: Smoking a single cigarette rapidly reduces combined concentrations of nitrate and nitrite and concentrations of antioxidants in plasma. Circulation 2002;105:1155–1157.
10.
Lindberg A, Jonsson AC, Ronmark E, Lundgren R, Larsson LG, Lundback B: Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor’s diagnosis, symptoms, age, gender, and smoking habits. Respiration 2005;72:471–479.
11.
Liu J, Thomas PS: Exhaled nitric oxide and NOx in exhaled breath condensate in COPD patients (abstract). Respirology 2005;10:A65.
12.
Yildiz F, Kaur AC, Ilgazli A, Celikoglu M, Kacar Ozkara S, Paksoy N, Ozkarakas O: Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration 2000;67:71–76.
13.
van Beurden WJ, Harff GA, Dekhuijzen PN, van der Poel-Smet SM, Smeenk FW: Effects of inhaled corticosteroids with different lung deposition on exhaled hydrogen peroxide in stable COPD patients. Respiration 2003;70:242–248.
14.
Liu J, Thomas PS: Relationship between exhaled breath condensate volume and measurements of lung volumes. Respiration 2006;74:142–145.
15.
Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG: A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 1993;214:11–16.
16.
Deykin A, Massaro AF, Drazen JM, Israel E: Exhaled nitric oxide as a diagnostic test for asthma: online versus offline techniques and effect of flow rate. Am J Respir Crit Care Med 2002;165:1597–1601.
17.
Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA: Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J 2005;26:52–59.
18.
Barnes PJ: Alveolar macrophages in chronic obstructive pulmonary disease (COPD). Cell Mol Biol (Noisy-le-grand) 2004;50 Online pub:OL627–OL637.
19.
Vier C, Hecht B, Becher G, Rothe M, Hammerschmidt S, Wirtz H, Gillissen A: Clinical significance of H2O2, nitrite/nitrate and pH in exhaled breath condensate during and after acute COPD exacerbation (abstract). Am J Respir Crit Care Med 2005;171(suppl):A932.
20.
Montuschi P, Macagno F, Parente P, Valente S, Lauriola L, Ciappi G, Kharitonov SA, Barnes PJ, Ciabattoni G: Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax 2005;60:827–833.
21.
Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, Barnes PJ: Exhaled 8-isoprostane as an In vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175–1177.
22.
Biernacki WA, Kharitonov SA, Barnes PJ: Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003;58:294–298.
23.
Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ: Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003;58:585–588.
24.
Corradi M, Pignatti P, Manini P, Andreoli R, Goldoni M, Poppa M, Moscato G, Balbi B, Mutti A: Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. Eur Respir J 2004;24:1011–1017.
25.
Repine JE, Bast A, Lankhorst I: Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997;156:341–357.
26.
Haight RR, Gordon RL, Brooks SM: The effects of age on exhaled breath nitric oxide levels. Lung 2006;184:113–119.
27.
Wei XM, Kim HS, Kumar RK, Heywood GJ, Hunt JE, McNeil HP, Thomas PS: Effects of cigarette smoke on degranulation and NO production by mast cells and epithelial cells. Respir Res 2005;6:108.
28.
Balint B, Donnelly LE, Hanazawa T, Kharitonov SA, Barnes PJ: Increased nitric oxide metabolites in exhaled breath condensate after exposure to tobacco smoke. Thorax 2001;56:456–461.
29.
Barnes PJ, Adcock IM, Ito K: Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552–563.
30.
Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902–1909.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.